1. Home
  2. SLN vs MLAC Comparison

SLN vs MLAC Comparison

Compare SLN & MLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • MLAC
  • Stock Information
  • Founded
  • SLN 1994
  • MLAC 2024
  • Country
  • SLN United Kingdom
  • MLAC United States
  • Employees
  • SLN N/A
  • MLAC N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • MLAC
  • Sector
  • SLN Health Care
  • MLAC
  • Exchange
  • SLN Nasdaq
  • MLAC NYSE
  • Market Cap
  • SLN 273.9M
  • MLAC 318.0M
  • IPO Year
  • SLN N/A
  • MLAC 2024
  • Fundamental
  • Price
  • SLN $6.11
  • MLAC $10.27
  • Analyst Decision
  • SLN Buy
  • MLAC
  • Analyst Count
  • SLN 5
  • MLAC 0
  • Target Price
  • SLN $32.60
  • MLAC N/A
  • AVG Volume (30 Days)
  • SLN 105.4K
  • MLAC 22.0K
  • Earning Date
  • SLN 08-14-2025
  • MLAC 01-01-0001
  • Dividend Yield
  • SLN N/A
  • MLAC N/A
  • EPS Growth
  • SLN N/A
  • MLAC N/A
  • EPS
  • SLN N/A
  • MLAC N/A
  • Revenue
  • SLN $27,701,000.00
  • MLAC N/A
  • Revenue This Year
  • SLN N/A
  • MLAC N/A
  • Revenue Next Year
  • SLN N/A
  • MLAC N/A
  • P/E Ratio
  • SLN N/A
  • MLAC $419.01
  • Revenue Growth
  • SLN N/A
  • MLAC N/A
  • 52 Week Low
  • SLN $1.97
  • MLAC $9.94
  • 52 Week High
  • SLN $22.47
  • MLAC $10.28
  • Technical
  • Relative Strength Index (RSI)
  • SLN 55.70
  • MLAC N/A
  • Support Level
  • SLN $6.10
  • MLAC N/A
  • Resistance Level
  • SLN $6.67
  • MLAC N/A
  • Average True Range (ATR)
  • SLN 0.39
  • MLAC 0.00
  • MACD
  • SLN -0.02
  • MLAC 0.00
  • Stochastic Oscillator
  • SLN 59.70
  • MLAC 0.00

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About MLAC MOUNTAIN LAKE ACQUISITION CORP

Mountain Lake Acquisition Corp is a blank check company.

Share on Social Networks: